|  |  |  |
| --- | --- | --- |
| **DRUG TYPE OR USE** | **PURPOSE** | **PBAC OUTCOME** |
| Biosimilar medicines | The PBAC considered the marking as equivalent (i.e. “a” flagging) in the Schedule of Pharmaceutical Benefits (the Schedule) of a biosimilar medicine with its reference medicine.  Note: the reference medicine is the medicine against which the new medicine has demonstrated biosimilarity. | The PBAC indicated it would consider the marking of equivalent (i.e. “a” flagging) in the Schedule of Pharmaceutical Benefits (the Schedule) of biosimilar medicines with their reference medicine on a case by case basis, taking into account the evidence presented in each submission to list a biosimilar medicine.  The PBAC further considered PBS subsidy of biosimilar medicines at its special meeting on 17 April 2015. The outcomes of that meeting will be published separately. |